ArticleVirulence2020
Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study.
Article in Virulence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiological, Radiographical, and Laboratorial Characteristics of Chinese Asymptomatic Cases With COVID-19: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- Article
- COVID-19 Screening Score for Patients without Acute Respiratory Symptoms Undergoing Emergency Medical Procedures in Indonesia.The American journal of tropical medicine and hygiene · 2023Article
- COVID-19 positive cases among asymptomatic individuals during the second wave in Ndola, Zambia.African journal of laboratory medicine · 2023Article
- SARS-CoV-2 versus other minor viral infection on kidney injury in asymptomatic and mildly symptomatic patients.Virulence · 2022Review
- Out-of-hospital cardiac arrest and in-hospital mortality among COVID-19 patients: A population-based retrospective cohort study.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2022Article
- Laboratory information management system for COVID-19 non-clinical efficacy trial data.Laboratory animal research · 2022Article
- Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Predicting progression to severe COVID-19 using the PAINT score.BMC infectious diseases · 2022Article
- Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.Molecular biomedicine · 2022Review
- Current Artificial Intelligence (AI) Techniques, Challenges, and Approaches in Controlling and Fighting COVID-19: A Review.International journal of environmental research and public health · 2022Review
- Changes in paediatric dental clinic after reopening during COVID-19 pandemic in Wuhan: a retrospective study.BMJ open · 2022Article
- A stochastic contact network model for assessing outbreak risk of COVID-19 in workplaces.PloS one · 2022Article
- Article
- ABO blood grouping and COVID-19: a hospital-based study in Eastern India.The Egyptian journal of medical human genetics · 2022Article
- Clinical outcomes of initially asymptomatic patients with COVID-19: a Korean nationwide cohort study.Annals of medicine · 2021Article
- Article
- Critical appraisal of the mechanisms of gastrointestinal and hepatobiliary infection by COVID-19.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Comprehensive Survey of Using Machine Learning in the COVID-19 Pandemic.Diagnostics (Basel, Switzerland) · 2021Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, has spread globally since the end of 2019. Asymptomatic carriers are of great concern as they can undermine the interventions to stop the pandemic. However, there is limited information about the characteristics and outcomes of the asymptomatic patients. Therefore, we conducted this retrospective study and retrieved data of 79 asymptomatic COVID-19 patients at admission from three designated hospitals in Wuhan, China. The asymptomatic patients could happen at any age, ranged from 9 to 96 years. These patients also had lower levels of alanine aminotransferase and C-reactive protein. Patchy shadowing was the most common manifestation in computed tomography scan. Some asymptomatic carriers developed mild or moderate symptoms during hospitalization. Age and comorbidities, especially hypertension, may be predictive factors for symptom development in the initially asymptomatic carriers at admission. Early detection and treatment for these presymptomatic patients before symptom onset can shorten the communicable period for the coronavirus and reduce the occurrence of severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.